Skip to main content

Table 4 Randomized placebo-controlled trials with oral glycoprotein IIb/IIIa inhibitors

From: Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease

Trial (number of patients)

Agent tested

Indications

Entry criteria

Primary endpoints

EXCITE (7232)

Xemilofiban

PCI

Patients with angiographic evidence of

Death, MI, and recurrent revascularization,

   

significant CAD requiring PCI

at 30 and 182 days

OPUS-TIMI 16

Orofiban

ACS

Unstable coronary syndromes; Q-wave

Death, MI, and recurrent ischemia,

(10,302)

  

MI, non-Q-wave MI, and UA, in preceding

revascularization, or stroke, at 30 days and

   

72 hours with either ECG changes,

6 months

   

enzyme elevation, or prior CAD

 

SYMPHONY (9233)

Sibrafiban

ACS

ACS event after stabilization

Death, MI, and severe recurrent ischemia,

    

at 90 days

SECONDSYMPHONY

Sibrafiban

ACS

ACS event after stabilization

Death, MI, and severe recurrent ischemia,

(6671)

   

at 90 days

BRAVO (9200)

Lotrafiban

ACS + CVA

Recent MI, UA, TIA or stroke, or PVD

Death, stroke, recurrent ischemia, or

    

revascularization, at 6 months-2 years

    

(stopped prematurely)

  1. ACS, Acute coronary syndromes; CAD, coronary artery disease; CVA, cerebrovascular accident; ECG, electrocardiogram; MI, myocardial infarction; PCI, percutaneous coronary interventions; PVD, peripheral vascular disease; TIA, transient ischemic attack; UA, unstable angina.
Back to article page

Trials

ISSN: 1745-6215